Dawn Belt Davis

List of Publications by Year
in descending order

47 papers	2,548 citations	236925 25 h-index	254184 43 g-index
50 all docs	50 docs citations	50 times ranked	3828 citing authors

#	Article	IF	Citations
1	A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility. Genome Research, 2008, 18, 706-716.	5.5	320
2	Thioredoxinâ€interacting protein deficiency induces Akt/Bclâ€xL signaling and pancreatic betaâ€cell mass and protects against diabetes. FASEB Journal, 2008, 22, 3581-3594.	0.5	194
3	Normal myoblast fusion requires myoferlin. Development (Cambridge), 2005, 132, 5565-5575.	2.5	183
4	Attention to Background Strain Is Essential for Metabolic Research: C57BL/6 and the International Knockout Mouse Consortium. Diabetes, 2016, 65, 25-33.	0.6	181
5	Calcium-sensitive Phospholipid Binding Properties of Normal and Mutant Ferlin C2 Domains. Journal of Biological Chemistry, 2002, 277, 22883-22888.	3.4	169
6	Myoferlin, a candidate gene and potential modifier of muscular dystrophy. Human Molecular Genetics, 2000, 9, 217-226.	2.9	161
7	Myne-1, a spectrin repeat transmembrane protein of the myocyte inner nuclear membrane, interacts with lamin A/C. Journal of Cell Science, 2002, 115, 61-70.	2.0	138
8	Myne-1, a spectrin repeat transmembrane protein of the myocyte inner nuclear membrane, interacts with lamin A/C. Journal of Cell Science, 2002, 115, 61-70.	2.0	116
9	Pancreatic Î²-Cell Proliferation in Obesity. Advances in Nutrition, 2014, 5, 278-288.	6.4	97
10	Pyruvate Kinase Controls Signal Strength in the Insulin Secretory Pathway. Cell Metabolism, 2020, 32, 736-750.e5.	16.2	88
11	Laparoscopic reversal of Roux-en-Y gastric bypass: Technique and utility for treatment of endocrine complications. Surgery for Obesity and Related Diseases, 2014, 10, 36-43.	1.2	84
12	FoxM1 Is Up-Regulated by Obesity and Stimulates Î²-Cell Proliferation. Molecular Endocrinology, 2010, 24, 1822-1834.	3.7	81
13	Interleukin 6 protects pancreatic Î² cells from apoptosis by stimulation of autophagy. FASEB Journal, 2017, 31, 4140-4152.	0.5	78
14	Dysferlin Protein Analysis in Limb-Girdle Muscular Dystrophies. Journal of Molecular Neuroscience, 2001, 17, 71-80.	2.3	67
15	Cholecystokinin Is Up-Regulated in Obese Mouse Islets and Expands Î²-Cell Mass by Increasing Î²-Cell Survival. Endocrinology, 2010, 151, 3577-3588.	2.8	58
16	Glucagon-Like Peptide-1 Regulates Cholecystokinin Production in Î²-Cells to Protect From Apoptosis. Molecular Endocrinology, 2015, 29, 978-987.	3.7	46
17	Roux en Y gastric bypass hypoglycemia resolves with gastric feeding or reversal: Confirming a non-pancreatic etiology. Molecular Metabolism, 2018, 9, 15-27.	6.5	43
18	A Retrospective Study Comparing Neutral Protamine Hagedorn Insulin With Glargine As Basal Therapy In Prednisone-Associated Diabetes Mellitus In Hospitalized Patients. Endocrine Practice, 2012, 18, 712-719.	2.1	41

#	Article	IF	Citations
19	Enriching Islet Phospholipids With Eicosapentaenoic Acid Reduces Prostaglandin E2 Signaling and Enhances Diabetic Î²-Cell Function. Diabetes, 2017, 66, 1572-1585.	0.6	41
20	Distinct differences in the responses of the human pancreatic Î²-cell line EndoC-Î²H1 and human islets to proinflammatory cytokines. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 309, R525-R534.	1.8	39
21	Tcf19 is a novel islet factor necessary for proliferation and survival in the INS-1 Î²-cell line. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E600-E610.	3.5	33
22	Intra-islet GLP-1, but not CCK, is necessary for Î²-cell function in mouse and human islets. Scientific Reports, 2020, 10, 2823.	3.3	31
23	PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3235-e3248.	3.6	31
24	Multiple endocrine neoplasia 2A syndrome presenting as peripartum cardiomyopathy due to catecholamine excess. European Journal of Endocrinology, 2004, 151, 771-777.	3.7	30
25	Cholecystokinin expression in the Î²-cell leads to increased Î²-cell area in aged mice and protects from streptozotocin-induced diabetes and apoptosis. American Journal of Physiology - Endocrinology and Metabolism, 2015, 309, E819-E828.	3.5	30
26	Contamination with E1A-Positive Wild-Type Adenovirus Accounts for Species-Specific Stimulation of Islet Cell Proliferation by CCK: A Cautionary Note. Molecular Endocrinology, 2010, 24, 464-467.	3.7	25
27	Transgenic expression of the human growth hormone minigene promotes pancreatic Î²-cell proliferation. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 309, R788-R794.	1.8	16
28	Systemic Metabolic Alterations Correlate with Islet-Level Prostaglandin E2 Production and Signaling Mechanisms That Predict Î²-Cell Dysfunction in a Mouse Model of Type 2 Diabetes. Metabolites, 2021, 11, 58.	2.9	16
29	Ultrahigh-Resolution Mass Spectrometry-Based Platform for Plasma Metabolomics Applied to Type 2 Diabetes Research. Journal of Proteome Research, 2021, 20, 463-473.	3.7	15
30	Overexpression of Pre-Pro-Cholecystokinin Stimulates Î²-Cell Proliferation in Mouse and Human Islets with Retention of Islet Function. Molecular Endocrinology, 2008, 22, 2716-2728.	3.7	14
31	Glucagonâ€•like peptideâ€•1 and cholecystokinin production and signaling in the pancreatic islet as an adaptive response to obesity. Journal of Diabetes Investigation, 2016, 7, 44-49.	2.4	10
32	Human Islet Expression Levels of Prostaglandin E₂ Synthetic Enzymes, But Not Prostaglandin EP3 Receptor, Are Positively Correlated with Markers of Î²-Cell Function and Mass in Nondiabetic Obesity. ACS Pharmacology and Translational Science, 2021, 4, 1338-1348.	4.9	10
33	Giant myelolipomas and inadvertent bilateral adrenalectomy in classic congenital adrenal hyperplasia. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 150079.	0.5	10
34	The gastrin-releasing peptide analog bombesin preserves exocrine and endocrine pancreas morphology and function during parenteral nutrition. American Journal of Physiology - Renal Physiology, 2015, 309, G431-G442.	3.4	9
35	Differential Expression of Ormdl Genes in the Islets of Mice and Humans with Obesity. IScience, 2020, 23, 101324.	4.1	9
36	Successful in vitro fertilization and generation of transgenics in Black and Tan Brachyury (BTBR) mice. Transgenic Research, 2016, 25, 847-854.	2.4	8

#	Article	IF	Citations
37	The influence of intermittent hypoxia, obesity, and diabetes on male genitourinary anatomy and voiding physiology. American Journal of Physiology - Renal Physiology, 2021, 321, F82-F92.	2.7	7
38	TCF19 Impacts a Network of Inflammatory and DNA Damage Response Genes in the Pancreatic Î²-Cell. Metabolites, 2021, 11, 513.	2.9	6
39	Cholecystokinin attenuates Î²-cell apoptosis in both mouse and human islets. Translational Research, 2022, 243, 1-13.	5.0	5
40	The Importance of Exclusion of Obstructive Sleep Apnea During Screening for Adrenal Adenoma and Diagnosis of Pheochromocytoma. Journal of Investigative Medicine High Impact Case Reports, 2015, 3, 232470961560706.	0.6	2
41	Imaging and therapy of diabetes: State of the art. Advanced Drug Delivery Reviews, 2019, 139, 1-2.	13.7	2
42	Pancreatic Stellate Cells Prolong Ex Vivo Islet Viability and Function and Improve Engraftment. Stem Cells Translational Medicine, 2022, 11, 630-643.	3.3	2
43	Tcf19 Knockout Mouse Islets Have Increased Stressâ€related Gene Expression and Reduced Proliferative Capacity. FASEB Journal, 2020, 34, 1-1.	0.5	1
44	FoxM1 Is Up-Regulated by Obesity and Stimulates Î²-Cell Proliferation. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4084-4084.	3.6	0
45	Roux-en-Y Gastric Bypass Hypoglycemia Resolves with Gastric Feeding or Reversal: Confirmation of a Nonpancreatic Mechanism. Journal of the American College of Surgeons, 2016, 223, e1.	0.5	0
46	FoxM1 Is Up-Regulated by Obesity and Stimulates Î²-Cell Proliferation. Endocrine Reviews, 2010, 31, 606-607.	20.1	0
47	2137-P: Cholecystokinin Protects Mouse Pancreatic Beta Cells against Cytokine Insult through the Cholecystokinin A Receptor. Diabetes, 2019, 68, .	0.6	0